Selective cyclooxygenase 2 inhibitor induces indefinite survival of fully allogeneic cardiac grafts and generates CD4+ regulatory cells  Takeshi Yokoyama,

Slides:



Advertisements
Similar presentations
Of mice and men and surgical transcatheter aortic valve insertion
Advertisements

Manuel J. Antunes, MD, PhD, DSc 
David D. Yuh, MD, Kimberly L. Gandy, MD, Bruce A
Tracheal regeneration: Myth or fact?
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
The use of technetium tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection  Patrick W. Vriens, MDa, Francis G. Blankenberg,
Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Prevention of the second stage of epithelial loss is a potential novel treatment for bronchiolitis obliterans  Yunge Zhao, MD, PhD, John F. Steidle, BA,
Effects of azithromycin and tanomastat on experimental bronchiolitis obliterans  Katharina Krenn, MD, Matthias Gmeiner, MD, PhD, Patrick Paulus, MD, Nezir.
Exogenous surfactant attenuation of ischemia–reperfusion injury in the lung through alteration of inflammatory and apoptotic factors  Bart P. van Putte,
Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model  Ashok Babu, MD, Xianzhong.
Physical exercise reduces transplant arteriosclerosis in a mouse aorta transplantation model  Wiebke Sommer, MD, Ann-Kathrin Knöfel, PhD, Nicole Izykowski,
Christopher G. A. McGregor, MB, William R
Preventing Allograft Rejection by Targeting Immune Metabolism
Building a bioartificial heart: A 3-song saga
Right internal thoracic artery or saphenous vein grafting
Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W
Intrinsic cardiac stem cells are essential for regeneration
Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 
Elevated messenger RNA expression and plasma protein levels of osteopontin and matrix metalloproteinase types 2 and 9 in patients with ascending aortic.
Form ever follows function
William M. DeCampli, MD, PhD 
Long-term patient and allograft outcomes of renal transplant recipients undergoing cardiac surgery  Rodolfo V. Rocha, MD, Diana Zaldonis, MPH, Vinay Badhwar,
Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation  Yosuke Tanaka, MD, Tomomi Hasegawa, MD, PhD,
Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells 
Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.
Cardiac dysfunction induced by experimental myocardial infarction impairs the host defense response to bacterial infection in mice because of reduced.
The lord of the rings  Antonio Miceli, MD, PhD 
Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non–small cell lung cancer 
Aldo R. Castañeda, MD, PhD: Recipient of the Lifetime Achievement Award and 74th president of The American Association for Thoracic Surgery  Pedro J.
Yang Zhang, MD, Haiquan Chen, MD, PhD 
Aditya K. Kaza, MD  The Journal of Thoracic and Cardiovascular Surgery 
Seeing a tree through the forest: Precision medicine tools can enhance donor allocation in heart transplantation  Vishnu Vasanthan, MD, Paul W.M. Fedak,
Occult active giant cell aortitis necessitating surgical repair
Juan N. Pulido, MD  The Journal of Thoracic and Cardiovascular Surgery 
Rohit K. Singal, MD, MSc, FRCSC, Rakesh C. Arora, MD, PhD, FRCSC 
Innovation and science: The future of valve design
The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery  Vinay Badhwar, MD  The Journal of Thoracic and.
It's not “just a shunt” but sometimes it should be…
Volume 8, Issue 5, Pages (May 2017)
Experience from an American Association for Thoracic Surgery Foundation for Thoracic Surgery Training Fellowship: Lung transplantation in Toronto General.
Implanted pedicled autologous pericardium mimics vasculature tissue: Case report  Naoki Masaki, MD, Osamu Adachi, MD, PhD, Shunsuke Kawamoto, MD, PhD,
A first start for lung transplantation?
Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD 
Impact of low donor to recipient weight ratios on cardiac transplantation  Senthil Nathan Jayarajan, MD, Sharven Taghavi, MD, Eugene Komaroff, PhD, Abeel.
Derrick Y. Tam, MD, Stephen E. Fremes, MD, MSc 
Passing the torch The Journal of Thoracic and Cardiovascular Surgery
Biomaterials for heart valve replacement: Conjectures and refutations
Importance of thymus to maintain operational tolerance to fully allogeneic cardiac grafts  Masanori Niimi, MD, PhD, Nozomu Shirasugi, MD, Yosifumi Ikeda,
Volume 71, Issue 11, Pages (June 2007)
Innovation in cardiothoracic surgical training
Inhibition of human allergic T-cell responses by IL-10–treated dendritic cells: Differences from hydrocortisone-treated dendritic cells  Iris Bellinghausen,
The origins of open heart surgery at the University of Minnesota 1951 to 1956  Richard A. DeWall, MD  The Journal of Thoracic and Cardiovascular Surgery 
The Journal of Thoracic and Cardiovascular Surgery
Discussion The Journal of Thoracic and Cardiovascular Surgery
Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau 
Tissue valve, nitinol stent, or storage solution
The future of cardiac surgery training: A survival guide
The continuing challenge of congenital heart disease in China
Heidi Goerler, MD, Andre Simon, MD, Gregor Warnecke, MD, Anna L
“The more things change…”: The challenges ahead
Toward a more rational approach in treating type B aortic dissection
Apples remain apples NO matter what
Of mice and men… The Journal of Thoracic and Cardiovascular Surgery
Did you like Terminator 3 better than Terminator 2
Steven R. Meyer, MD, Jeevan Nagendran, BSc, Leena S. Desai, Gina R
Commentary: Evaluation of primary graft dysfunction after lung transplantation—It is time to teach an old dog new tricks!  W. Hampton Gray, MD, P. Michael.
Calpain inhibitors: The aspirin of the 21st century?
Presentation transcript:

Selective cyclooxygenase 2 inhibitor induces indefinite survival of fully allogeneic cardiac grafts and generates CD4+ regulatory cells  Takeshi Yokoyama, MD, Osamu Aramaki, MD, Tadatoshi Takayama, MD, Seigo Takano, MD, Qi Zhang, MSc, Motohide Shimazu, MD, Masaki Kitajima, MD, Yoshifumi Ikeda, MD, Nozomu Shirasugi, MD, Masanori Niimi, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 130, Issue 4, Pages 1167-1174 (October 2005) DOI: 10.1016/j.jtcvs.2005.06.031 Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Histologic studies of harvested cardiac grafts, with hematoxylin and eosin staining (A-D) and COX-2 immunostaining (E-H). A, C57BL/10 allograft obtained 100 days after transplantation from a CBA recipient given 20 mg/kg NS-398 the day of transplantation. B, CBA graft (syngeneic graft) harvested from a CBA recipient 100 days after transplantation. C, C57BL/10 allograft harvested from an NS-398–treated CBA recipient 7 days after transplantation. D, C57BL/10 allograft harvested from an untreated CBA recipient 7 days after transplantation (showing for positive control). (Hematoxylin and eosin stain; original magnification 50× and 100× [inset].) Immunohistochemistry studies of harvested cardiac allografts for cyclooxygenase 2 staining. E, C57BL/10 allograft harvested from an untreated CBA recipient 7 days after transplantation. F, C57BL/10 cardiac graft obtained immediately after harvesting from donor C57BL/10 mice. G, C57BL/10 allograft harvested from an NS-398–treated CBA recipient 14 days after transplantation. H, C57BL/10 allograft harvested from an NS-398–treated CBA recipient 30 days after transplantation (cyclooxygenase-positive leukocytes [arrows]). (Original magnification 300×.) The Journal of Thoracic and Cardiovascular Surgery 2005 130, 1167-1174DOI: (10.1016/j.jtcvs.2005.06.031) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 A, Graft survival after adoptive transfer of splenocytes. CBA mice (primary recipients) were treated with 20 mg/kg NS-398 and underwent transplantation of C57BL/10 cardiac grafts the same day. One hundred days later, splenocytes (5 × 107) from the primary recipients with functioning allografts were adoptively transferred into naive CBA mice (secondary recipients) that were then given C57BL/10 cardiac grafts. Secondary recipients in the control group underwent adoptive transfer of splenocytes from naive CBA mice (#P < .01 between the 2 groups). B, Graft survival after adoptive transfer of CD4+ cells. CBA mice (primary recipients) were treated with 20 mg/kg NS-398 and underwent transplantation of C57BL/10 cardiac grafts the same day. One hundred days later, CD4+ cells were purified from the spleen in the primary recipients with functioning allografts by using positive selection with MACS CD4 Microbeads, and 2 × 107 CD4+ cells were adoptively transferred into naive secondary recipients that received transplantation of C57BL/10 hearts immediately afterward. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 1167-1174DOI: (10.1016/j.jtcvs.2005.06.031) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 A, Results of cell-proliferation assay in mixed leukocyte culture. Untreated CBA mice and mice treated with NS-398 (20 mg/kg) were given cardiac grafts from C57BL/10 mice. Seven days later, splenocytes (0.25 × 106 cells) from the CBA mice (responder cells) were cocultured with splenocytes from either C57BL/10 mice (stimulator cells; 1 × 106 cells) (#P < .01 between 2 groups). B and C, Levels of cytokines in the mixed leukocyte culture. Untreated CBA mice and mice treated with NS-398 (20 mg/kg) were given cardiac grafts from C57BL/10 mice. Seven days later, splenocytes (0.25 × 106 cells) from the CBA mice (responder cells) were cocultured with splenocytes from either C57BL/10 mice (stimulator cells; 1 × 106 cells) for 4 days. Levels of interleukin 4 (IL-4; B), interleukin 10 (IL-10; C), interleukin 2, and interferon γ in the mixed leukocyte culture were assessed by using enzyme-linked immunosorbent assays. There were no differences between groups in interleukin 2 or interferon γ levels (data not shown; #P < .01 and ##P < .05 between 2 groups). The Journal of Thoracic and Cardiovascular Surgery 2005 130, 1167-1174DOI: (10.1016/j.jtcvs.2005.06.031) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions